Lorbrena (lorlatinib) is considered medically necessary for patients meeting the
18 years of age or older AND
of metastatic non-small cell lung cancer (NSCLC) AND
anaplastic lymphoma kinase (ALK)-positive AND
disease has progressed on one of the following:
and at least one other ALK inhibitor (e.g. Alunbrig).
as the first ALK inhibitor therapy.
as the first ALD inhibitor therapy.
does not show evidence of progression of disease while on Lorbrena therapy.